Literature DB >> 19319498

[Kidney and hypertension].

I Quack1, L C Rump.   

Abstract

In patients with chronic kidney disease elevated blood pressure is a common finding, but primary hypertension can also damage healthy kidneys. Renal outcome is strictly dependent on blood pressure, no matter whether the kidneys are cause or consequence of hypertension. Furthermore, hypertension and kidney disease are strong cardiovascular risk factors. In every patient diagnosed with hypertension glomerular filtration rate has to be checked. Proteinuria and structural abnormalities of the kidneys should be ruled out. Patients with a decreased glomerular filtration rate, proteinuria or pathologic ultrasound should be seen by a nephrologist. A strict antihypertensive therapy (blood pressure <130/80 mmHg) can substantially improve the prognosis of hypertensive renal patients. In patients with kidney damage, inhibitors of the renin-angiotensin-system are preferred. To avoid adverse events a close monitoring of antihypertensive therapy is warranted.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19319498     DOI: 10.1007/s00108-008-2290-x

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  53 in total

1.  The COOPERATE trial: a letter of concern.

Authors:  Regina Kunz; Marcel Wolbers; Tracy Glass; Johannes F E Mann
Journal:  Lancet       Date:  2008-05-10       Impact factor: 79.321

2.  Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.

Authors:  J F Mann; H C Gerstein; J Pogue; J Bosch; S Yusuf
Journal:  Ann Intern Med       Date:  2001-04-17       Impact factor: 25.391

3.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

Review 4.  Heterogeneous responses to changes in dietary salt intake: the salt-sensitivity paradigm.

Authors:  F C Luft; M H Weinberger
Journal:  Am J Clin Nutr       Date:  1997-02       Impact factor: 7.045

Review 5.  Performance of creatinine-based estimates of GFR in kidney transplant recipients: a systematic review.

Authors:  Christine A White; David Huang; Ayub Akbari; Jocelyn Garland; Greg A Knoll
Journal:  Am J Kidney Dis       Date:  2008-05-02       Impact factor: 8.860

6.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

7.  Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.

Authors:  Leszek Tylicki; Przemysław Rutkowski; Marcin Renke; Wojciech Larczyński; Ewa Aleksandrowicz; Wiesława Lysiak-Szydlowska; Bolesław Rutkowski
Journal:  Am J Kidney Dis       Date:  2008-04-18       Impact factor: 8.860

8.  Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.

Authors:  Yoshiyuki Furumatsu; Yasuyuki Nagasawa; Kodo Tomida; Satoshi Mikami; Tetsuya Kaneko; Noriyuki Okada; Yoshiharu Tsubakihara; Enyu Imai; Tatsuya Shoji
Journal:  Hypertens Res       Date:  2008-01       Impact factor: 3.872

9.  [Sequelae of hypertenson: kidney disease].

Authors:  W H Hörl
Journal:  Internist (Berl)       Date:  2006-03       Impact factor: 0.743

Review 10.  Direct vasodilators and their role in hypertension management: minoxidil.

Authors:  D A Sica; T W Gehr
Journal:  J Clin Hypertens (Greenwich)       Date:  2001 Mar-Apr       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.